Literature DB >> 18052208

Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.

Alexander A Makarov1, Philipp O Tsvetkov, Claude Villard, Didier Esquieu, Bertrand Pourroy, Jacques Fahy, Diane Braguer, Vincent Peyrot, Daniel Lafitte.   

Abstract

Vinca alkaloids vinblastine and vincristine and some of their derivatives such as vinorelbine are widely used in therapy of leukemia and several solid tumors. Their action is associated with alterations of the mitotic spindle functions that prevent the cell cycle progression and lead to mitotic block. A number of studies show that some Vinca alkaloids inhibit CaM-target interaction. The newest microtubule inhibitor, vinflunine (Javlor), currently in clinical trials, is remarkably more active than vinblastine against a number of tumors. Moreover, vinflunine is significantly less toxic than other Vinca alkaloids. The high antitumor activity of this molecule is not well understood since it binds to tubulin with an overall affinity several-fold lower than that of vinblastine or vincristine. In this study, we examined the interaction of Ca2+-CaM with vinflunine, vinblastine, and stable tubule only polypeptide (STOP) by using a combination of thermodynamic and mass spectrometric approaches. We characterized the influence of Vinca alkaloids on Ca2+-CaM-STOP complex formation. Our results revealed different binding modes to Ca2+-CaM for vinflunine and vinblastine, highlighting that adding fluorine atoms on the cleavamine moiety of the Vinca alkaloid molecule is critical for the localization of the drug on calmodulin. We demonstrate that vinflunine is a better inhibitor for STOP binding to calmodulin than vinblastine. We suggest that vinflunine action on calmodulin can have an effect on microtubule dynamics. These data may contribute to a better understanding of the superior antitumor efficiency and lower toxicity of vinflunine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052208     DOI: 10.1021/bi701803s

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

Review 1.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

2.  Identification and inhibitory properties of a novel Ca(2+)/calmodulin antagonist.

Authors:  Josep Colomer; Allison A Schmitt; Eric J Toone; Anthony R Means
Journal:  Biochemistry       Date:  2010-05-18       Impact factor: 3.162

3.  Structural basis for the association of MAP6 protein with microtubules and its regulation by calmodulin.

Authors:  Julien Lefèvre; Philippe Savarin; Pierre Gans; Loïc Hamon; Marie-Jeanne Clément; Marie-Odile David; Christophe Bosc; Annie Andrieux; Patrick A Curmi
Journal:  J Biol Chem       Date:  2013-07-06       Impact factor: 5.157

4.  Study of possible interactions of tubulin, microtubular network, and STOP protein with mitochondria in muscle cells.

Authors:  Karen Guerrero; Claire Monge; Anna Brückner; Ulo Puurand; Lumme Kadaja; Tuuli Käämbre; Enn Seppet; Valdur Saks
Journal:  Mol Cell Biochem       Date:  2009-11-04       Impact factor: 3.396

5.  Stathmin/Op18 is a novel mediator of vinblastine activity.

Authors:  Francois Devred; Philipp O Tsvetkov; Pascale Barbier; Diane Allegro; Susan Band Horwitz; Alexander A Makarov; Vincent Peyrot
Journal:  FEBS Lett       Date:  2008-06-25       Impact factor: 4.124

6.  Stathmin potentiates vinflunine and inhibits Paclitaxel activity.

Authors:  Soazig Malesinski; Philipp O Tsvetkov; Anna Kruczynski; Vincent Peyrot; François Devred
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

Review 7.  Indole alkaloids from Catharanthus roseus: bioproduction and their effect on human health.

Authors:  Lorena Almagro; Francisco Fernández-Pérez; Maria Angeles Pedreño
Journal:  Molecules       Date:  2015-02-12       Impact factor: 4.411

8.  Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy.

Authors:  A Lehotzky; N Tokési; I Gonzalez-Alvarez; V Merino; M Bermejo; F Orosz; P Lau; G G Kovacs; J Ovádi
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2008-10-13       Impact factor: 4.226

9.  Mechanism of Zn2+ and Ca2+ Binding to Human S100A1.

Authors:  Viktoriia E Baksheeva; Andrei Yu Roman; Claude Villard; François Devred; Deborah Byrne; Dahbia Yatoui; Arthur O Zalevsky; Alisa A Vologzhannikova; Andrey S Sokolov; Sergei E Permyakov; Andrey V Golovin; Gary S Shaw; Philipp O Tsvetkov; Evgeni Yu Zernii
Journal:  Biomolecules       Date:  2021-12-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.